Please ensure Javascript is enabled for purposes of website accessibility

COVID-19 Nearing Pandemic Level, WHO Warns

By Brian Orelli, PhD - Updated Mar 10, 2020 at 12:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The head of the World Health Organization describes the threat of the coronavirus outbreak reaching pandemic proportions as "very real."

Though at the moment just four countries -- China, South Korea, Italy, and Iran -- account for a vast majority of confirmed COVID-19 cases, World Health Organization Director-General Tedros Adhanom Ghebreyesus thinks we're getting close to experiencing a pandemic level event.

"Now that the virus has a foothold in so many countries, the threat of a pandemic has become very real," Tedros said at a news conference, referring to the novel coronavirus.

Tedros does think the world can still keep the outbreak under control. We're "not at the mercy of the virus," he said, adding that it would be the first pandemic in history that could be controlled.

WHO officials noted that reducing the flow of people out of the hardest-hit areas -- Wuhan and Hubei provinces in China, and the northern region of Lombardy and parts of Veneto in Italy -- has helped stem the spread of the coronavirus. Those measures have also given other areas time to prepare, which should result in better responses and better outcomes.

People on the sidewalk wearing face masks

Image source: Getty Images.

Multiple drugmakers are testing treatments for COVID-19. The most advanced drugs available to be studied are antiviral medications that were developed for other viruses, such as Gilead Sciences' (GILD 0.80%) remdesivir and Johnson & Johnson's (JNJ 1.46%) HIV treatment Prezcobix.

Other companies, including Moderna (MRNA 0.70%) and Inovio Pharmaceuticals (INO -3.48%), have developed potential vaccines against the virus. Clinical trials for those are scheduled to start shortly, but even assuming they are effective, it'll likely be a year or more before they're ready for widespread use.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$63.08 (0.80%) $0.50
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$182.29 (1.46%) $2.63
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.94 (-3.48%) $0.07
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$144.27 (0.70%) $1.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.